Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche product predicted to accumulate fifth of breast cancer drug market in 2017

Roche product predicted to accumulate fifth of breast cancer drug market in 2017

22nd October 2008

Roche is expected to accumulate more than a fifth of total breast cancer drug sales in the UK, US, Japan, France, Italy, Germany and Spain in 2017 with one of its products, according to a report.

Sales of Genentech/Roche/Chugai’s Avastin in the US and Europe and its launch in Japan will drive the cancer drug market, the new Pharmacor report from Decision Resources – entitled Breast Cancer – found.

Furthermore, Herceptin – from the same company – continues to head the market segment for human epidermal growth factor receptor-2 (HER2) positive breast cancer, the report said.

Dr Niamh Murphy, analyst at Decision Resources, said: "There is a significant unmet need for the development of effective agents for the treatment of triple-negative breast cancer."

This is due to the "lack of receptor expression results in resistance to conventional hormonal and targeted therapies" which leaves chemotherapy as the only choice for triple-negative breast cancer patients, she explained.

People looking for scientific sales jobs may be interested Roche’s other products, which include MabThera and Viracept.
ADNFCR-1050-ID-18837876-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.